Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Who cares what celularity is doing. They are going after different things than PSTI. PSTI isn’t going to be a monopoly of placenta cell research. Honestly it’s probably better to have multiple companies pushing placenta cell therapies so it can show the worth of the science. All PSTI needs to worry about is PSTI and getting approvals on their clinical trials.
Scott,
I do my best to answer your questions when I see them.
In regards to your milestone question, I am in agreement with you on this. They didn’t come anywhere close to hitting milestones. I believe they made progress on some milestone but no where being able to check the box as complete.
Totally agree. We are all wanting the same thing and that’s making money. Some have different opinions than others and I get that. Let me clarify, I don’t have a problem with you or anyone else saying the management sucks. I just don’t want to hear the same blanket statement that the “twins” suck or this is rocketing to the moon. Neither adds value for anyone else who wants to learn more about this company.
What is you thoughts on the advisory committee? I see they have one but I don’t see them touting the company. That to me is a bigger issue then the execs not cutting it. They should be on the frontline getting the Pluristem name out, while our execs do as you stated before, making sure the company hits specific milestones. Now granted, Bio timelines are easily missed due to numerous outside factors (enrollment, fda guidance...) and IMO I’m ok with 6-10 months of variance, but nothing more.
Scott,
Thanks for the reply. I to, think management could be better in the clarity of what is happening. And thanks for the heads up about the vote in a couple months.
I like the idea of offering some shares to bring in some other talent. Which companies do you think they should go after?
Let’s say we can’t get the change in management, what else can we do to help out the current management? Are we to far in the hole that it isn’t worth it? Things we could do is ask some of these cancer research companies if they even know about Pluristem and if so, what is their thoughts.
I personally feel like the science is legit but the art of stem cells overal has a bit of stain to it. So many news stories of black market stem cell treatments paints a bad picture for the legit ones. I wonder how much this really impacts the company.
Cool story bro!
Gary,
Really appreciate the read on this. And again I wish you the best and full recovery!
Funny you mention the use in injecting to your knees. That’s really how I found out about stem cells from hearing athletes getting it done and proven its worth. Further looking into stem cells, I came across Pluristem.
I am really surprised that the number of indications that stem cells or placental cells could potentially work for, it still a bit of a mystery technique. I guess these procedures, if proven affective, will cut into the multi, multi-billion dollar industries. I think some mentioned before, that some of these companies could be bought out and scraped just to keep it from impacting the purchasing companies bottom line. Hopefully that never happens especially if proven its worth.
Also, I wonder what it would take to get someone else on board to push the benefits of this therapy. For instance going back to my athletic tie, someone at the Jimmy V foundation that has a strong presence in the cancer world. I guess this would go along with the recent talks about what more management could do.
Again, thanks for your post and very informative.
Scott,
I know you addressed this to Spidey but he didn’t make the jump from R&D researcher at Teva to VP at Pluristem. He held two other roles with Pluristem prior to becoming VP. But to answer your initial question, no a researcher to VP is not a common leap. However he made is way up the chain having been a director prior to being a VP.
Only thing I could find that pointed out all positions prior to becoming a VP
http://pluristem.netron-webs.com/index.php/about2/management/85-management-team/543-lior-raviv.html
Interesting info, as I wasn’t aware of big block trades being made.
As for the after market trades, you can see that on the iHub chart. The green color trades on the chart typically signifies the daily short volume. And since it was Friday, MMs can’t go through the weekend letting those share be unaccounted for. So you’ll see that volume being covered in the after market.
Thanks for this post and your previous one. Lots of info for me to digest.
Since I’m rather green on stem cells therapies, how does this typically work? For instance, you’re taking this for ARS but your body has another deficancy going on. How does it know to treat what? Does it need to be injected into certain areas for certain situations? Do different intervals occur for different scenarios? Not looking for anything detailed just opening up dialog. Please excuse my non-medical wording and thanks in advance.
Gary, sorry to read about your situation. I wish you good health and a speedy recovery. I do appreciate you being able to openly talk about your situation and how it could compare with the way PSTI moves forward. I’m no expert on stem cells but between yours and spidey’s posts, it certainly helps understand the product more.
Drop slightly, possibly. Plummet? Highly unlikley. Normally the opposite occurs when the daily short volume is a high percent. MMs generally need to cover at the ask and not the bid. Also, it looks like the majority of those short shares were covered after the market closed, so this is all a moot point.
Nicely played! I wish I held onto my MDXG shares. Never would have guessed they would have reached their current level.
As for currently, I’m looking at PSTI. Pretty volatile for some short term value. Has some long term if things come along.
I hear ya. Let’s get this party started. What’s new out there on the market? I’m sure I’ve missed a ton since I’ve been out.
What name did I call you and how did I become a pumper? Also I addressed your concern of a new company getting Orphan Drug Designation and you decided not to read that because it didn’t fit your agenda. Try reading my first two posts again about my opinion.
Please figure out the difference between what’s a fact and what’s an opinion. Again, outside of the share price is your opinion, not a fact. Also, I don’t care what happened 1,2 or 10 years ago. I care about now. Sorry you weren’t smart enough to realize you bought at a high and still weren’t smart enough to get out when the price dropped. But please keep posting your brilliance within the market and your extensive opinion of this stock. Good day.
I have no idea what you just tried to write. Reminds me of a dog chasing his tail. I have been reading this board for several months now and the only “fact” you have posted is the current share price. Now I’m not coming in here and saying this is going to the moon nor guaranteeing any future success of this company. All I care about is making money and you can’t do that by falling in love or belittling a stock. Good luck in your investments.
I must have missed the facts you state. I did read your opinion that this is a concern. While I agree somewhat, that another company with a competing drug is a concern, Enzychem isn’t that conerncing. Did you read what info they provided in there PR? I posted the link below and skip to the 6th paragraph. See anything fishy there? Just because a company receives Orphan Drug Designation doesn’t mean they will get a priority review voucher. Also, it seems like they care more about selling that voucher then taking their product to market.
If I were to worry about a competing company, and I’m not at this point, it would be Soligenix. They received Orphan Drug Designation for there ARS product in 2013. They need a partner to help bring it through trials so they may or may not ever move said product.
https://www.prnewswire.com/news-releases/enzychem-lifesciences-announces-the-fda-orphan-drug-designation-granted-to-ec-18-on-acute-radiation-syndrome-ars-300585325.html
What up my long lost fam?!
Please stop the fear-mongering. There are four products who have been granted orphan drug designation for ARS. Until one is actually approved by the FDA, any company can apply for this designation. Only one has the DOD looking into it. I will take my chances with that one.
I put LEDIF on my watch list. They are using a similar tech as verisante, but in a dental format. There product is FDA approved and are generating revs already.
http://finance.yahoo.com/news/led-medical-diagnostics-inc-patented-133000145.html
http://finance.yahoo.com/news/led-medical-diagnostics-reports-2012-022126642.html
http://finance.yahoo.com/news/led-medical-diagnostics-reports-2013-003507228.html
Your not going to get much out of it, other then the revs. 2nd quarter is where the real info will come from. You will see what is, or what is not happening overseas.
Not a whole lot positive, other then the vorsatech firm since they are still active. The wind firm makes me wonder some. I did notice that all these companies had relatively small share counts, so they weren't just selling shares. Now I didn't dig deep, so I am not sure if reverse splits were done to lower the counts. I am still holding here, but its rough. I do think verisante is the best of any that he has been involved in.
This should help you out MA
http://investing.businessweek.com/research/stocks/people/person.asp?personId=10879105&ticker=VRS:CN
I think it is a double edge sword, on this issue. Insurance coverage may limit what derms can charge. Right now they can charge whatever they want for scans. I have been following Lucid, since they are going through the regulatory approvals for insurance coverage. I haven't seen any update other then they where looking into the coverage.
Wish I were. I was out when it popped over 3
VRSEF
Easy on the kings. They win tonight I give them a 50/50 shot of making the playoffs. Lol.
No need for apologies. Lol. VRSEF has certainly taken its sweet time here but the future is bright. Might still be a little slow for a couple more months, due to 9.7 mil warrants @.50, set to expire in April. After that I am ready to see this go into Harleys 50 bagger territory!
There we go. Now I am off the hook of being MAs red headed step child if this goes south!
From my perspective, you are that mystery poster. Lol. Looking back on my posting history here, you were the person who responded to my first VRSEF question.
Not sure I can take credit for this one. When I joined this board it was already on the index.
Only a couple more days for the Feb warrants to expire. Hopefully after that we can see this back when it was first included on the PS index.
http://www.insidestocks.com/texpert.asp?sym=VRSEF&code=BCMM
This is great news. 10 devices sold now. Hopefully the momo can sustain through the prizm awards next Tuesday.
Dang i thought this was golf, lower score wins. C'mon IGXT! PS Index is looking good and is just warming up
Looking good. I think I may like the comments of those pictures better!
VRSEF
http://finance.yahoo.com/news/verisante-technology-inc-announces-expansion-202113829.html
Interesting going with the same company. I like it. Should get things up to speed quicker.
VRSEF- huge market to enter. Hopefully the Aussie dealer is around the corner.
IGXT for my WC